{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T12:23:00Z","timestamp":1792498980105,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T00:00:00Z","timestamp":1621987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T00:00:00Z","timestamp":1621987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81772778"],"award-info":[{"award-number":["81772778"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81902654"],"award-info":[{"award-number":["81902654"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81902644"],"award-info":[{"award-number":["81902644"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Progesterone resistance can significantly restrict the efficacy of conservative treatment for patients with endometrial cancer who wish to preserve their fertility or those who suffer from advanced and recurrent cancer. SREBP1 is known to be involved in the occurrence and progression of endometrial cancer, although the precise mechanism involved remains unclear. In the present study, we carried out microarray analysis in progesterone-sensitive and progesterone-resistant cell lines and demonstrated that SREBP1 is related to progesterone resistance. Furthermore, we verified that SREBP1 is over-expressed in both drug-resistant tissues and cells. Functional studies further demonstrated that the inhibition of SREBP1 restored the sensitivity of endometrial cancer to progesterone both in vitro and in vivo, and that the over-expression of SREBP1 promoted resistance to progesterone. With regards to the mechanism involved, we found that SREBP1 promoted the proliferation of endometrial cancer cells and inhibited their apoptosis by activating the NF-\u03baB pathway. To solve the problem of clinical application, we found that Fatostatin, an inhibitor of SREBP1, could increase the sensitivity of endometrial cancer to progesterone and reverse progesterone resistance by inhibiting SREBP1 both in vitro and in vivo. Our results highlight the important role of SREBP1 in progesterone resistance and suggest that the use of Fatostatin to target SREBP1 may represent a new method to solve progesterone resistance in patients with endometrial cancer.<\/jats:p>","DOI":"10.1038\/s41419-021-03762-0","type":"journal-article","created":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T09:03:14Z","timestamp":1622019794000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Fatostatin reverses progesterone resistance by inhibiting the SREBP1-NF-\u03baB pathway in endometrial carcinoma"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8625-237X","authenticated-orcid":false,"given":"Xiaohong","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3594-3901","authenticated-orcid":false,"given":"Kui","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4625-8165","authenticated-orcid":false,"given":"Chunping","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9634-4152","authenticated-orcid":false,"given":"Jie","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,26]]},"reference":[{"key":"3762_CR1","first-page":"7","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2020. CA 70, 7\u201330 (2020).","journal-title":"CA"},{"key":"3762_CR2","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.1200\/JCO.2006.08.8344","volume":"25","author":"K Ushijima","year":"2007","unstructured":"Ushijima, K. et al. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J. Clin. Oncol. 25, 2798\u20132803 (2007).","journal-title":"J. Clin. Oncol."},{"key":"3762_CR3","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/AOG.0b013e3182605bf1","volume":"120","author":"JI Sorosky","year":"2012","unstructured":"Sorosky, J. I. Endometrial cancer. Obstet. Gynecol. 120, 383\u2013397 (2012).","journal-title":"Obstet. Gynecol."},{"key":"3762_CR4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0304-3835(01)00462-1","volume":"167","author":"T Kaku","year":"2001","unstructured":"Kaku, T. et al. Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: central pathologic review and treatment outcome. Cancer Lett. 167, 39\u201348 (2001).","journal-title":"Cancer Lett."},{"key":"3762_CR5","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ygyno.2004.06.045","volume":"95","author":"PT Ramirez","year":"2004","unstructured":"Ramirez, P. T., Frumovitz, M., Bodurka, D. C., Sun, C. C. & Levenback, C. Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review. Gynecol. Oncol. 95, 133\u2013138 (2004).","journal-title":"Gynecol. Oncol."},{"key":"3762_CR6","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0092-8674(00)80213-5","volume":"89","author":"MS Brown","year":"1997","unstructured":"Brown, M. S. & Goldstein, J. L. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89, 331\u2013340 (1997).","journal-title":"Cell"},{"key":"3762_CR7","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1111\/j.1432-1033.1991.tb16052.x","volume":"198","author":"A Witkowski","year":"1991","unstructured":"Witkowski, A., Rangan, V. S., Randhawa, Z. I., Amy, C. M. & Smith, S. Structural organization of the multifunctional animal fatty-acid synthase. Eur. J. Biochem. 198, 571\u2013579 (1991).","journal-title":"Eur. J. Biochem."},{"key":"3762_CR8","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1158\/1541-7786.MCR-11-0206","volume":"10","author":"WC Huang","year":"2012","unstructured":"Huang, W. C., Li, X., Liu, J., Lin, J. & Chung, L. W. Activation of androgen receptor, lipogenesis, and oxidative stress converged by SREBP-1 is responsible for regulating growth and progression of prostate cancer cells. Mol. Cancer Res. 10, 133\u2013142 (2012).","journal-title":"Mol. Cancer Res."},{"key":"3762_CR9","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1006\/bbrc.2000.2262","volume":"269","author":"H Heemers","year":"2000","unstructured":"Heemers, H., Vanderhoydonc, F., Heyns, W., Verhoeven, G. & Swinnen, J. V. Progestins and androgens increase expression of Spot 14 in T47-D breast tumor cells. Biochem. Biophys. Res. Commun. 269, 209\u2013212 (2000).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"3762_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2017.49","volume":"6","author":"F Yin","year":"2017","unstructured":"Yin, F. et al. TIP30 regulates lipid metabolism in hepatocellular carcinoma by regulating SREBP1 through the Akt\/mTOR signaling pathway. Oncogenesis 6, e347 (2017).","journal-title":"Oncogenesis"},{"key":"3762_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2015.161","volume":"5","author":"HL Cai","year":"2015","unstructured":"Cai, H. L. et al. A potential mechanism underlying atypical antipsychotics-induced lipid disturbances. Transl. Psychiatry 5, e661 (2015).","journal-title":"Transl. Psychiatry"},{"key":"3762_CR12","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S0163-7827(01)00010-8","volume":"40","author":"H Shimano","year":"2001","unstructured":"Shimano, H. Sterol regulatory element-binding proteins (SREBPs): transcriptional regulators of lipid synthetic genes. Prog. Lipid Res. 40, 439\u2013452 (2001).","journal-title":"Prog. Lipid Res."},{"key":"3762_CR13","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.cell.2011.09.045","volume":"147","author":"AK Walker","year":"2011","unstructured":"Walker, A. K. et al. A conserved SREBP-1\/phosphatidylcholine feedback circuit regulates lipogenesis in metazoans. Cell 147, 840\u2013852 (2011).","journal-title":"Cell"},{"key":"3762_CR14","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1016\/j.peptides.2010.07.020","volume":"31","author":"XY Dong","year":"2010","unstructured":"Dong, X. Y. & Tang, S. Q. Insulin-induced gene: a new regulator in lipid metabolism. Peptides 31, 2145\u20132150 (2010).","journal-title":"Peptides"},{"key":"3762_CR15","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.repbio.2013.01.170","volume":"13","author":"MK Kowalik","year":"2013","unstructured":"Kowalik, M. K., Slonina, D., Rekawiecki, R. & Kotwica, J. Expression of progesterone receptor membrane component (PGRMC) 1 and 2, serpine mRNA binding protein 1 (SERBP1) and nuclear progesterone receptor (PGR) in the bovine endometrium during the estrous cycle and the first trimester of pregnancy. Reprod. Biol. 13, 15\u201323 (2013).","journal-title":"Reprod. Biol."},{"key":"3762_CR16","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.4161\/cc.20811","volume":"11","author":"W Li","year":"2012","unstructured":"Li, W. et al. Repression of endometrial tumor growth by targeting SREBP1 and lipogenesis. Cell Cycle 11, 2348\u20132358 (2012).","journal-title":"Cell Cycle"},{"key":"3762_CR17","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1097\/IGC.0000000000000004","volume":"23","author":"C Qiu","year":"2013","unstructured":"Qiu, C., Dongol, S., Lv, Q. T., Gao, X. & Jiang, J. Sterol regulatory element-binding protein-1\/fatty acid synthase involvement in proliferation inhibition and apoptosis promotion induced by progesterone in endometrial cancer. Int. J. Gynecol. Cancer 23, 1629\u20131634 (2013).","journal-title":"Int. J. Gynecol. Cancer"},{"key":"3762_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5904-x","volume":"19","author":"Y Gao","year":"2019","unstructured":"Gao, Y. et al. SREBP1 promotes the invasion of colorectal cancer accompanied upregulation of MMP7 expression and NF-kappaB pathway activation. BMC Cancer 19, 685 (2019).","journal-title":"BMC Cancer"},{"key":"3762_CR19","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/j.bbrc.2017.11.163","volume":"495","author":"H Yang","year":"2018","unstructured":"Yang, H. et al. SREBP1-driven lipid desaturation supports clear cell renal cell carcinoma growth through regulation of NF-kappaB signaling. Biochem. Biophys. Res. Commun. 495, 1383\u20131388 (2018).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"3762_CR20","doi-asserted-by":"publisher","first-page":"7320","DOI":"10.1074\/jbc.M210283200","volume":"278","author":"Y Choi","year":"2003","unstructured":"Choi, Y., Kawazoe, Y., Murakami, K., Misawa, H. & Uesugi, M. Identification of bioactive molecules by adipogenesis profiling of organic compounds. J. Biol. Chem. 278, 7320\u20137324 (2003).","journal-title":"J. Biol. Chem."},{"key":"3762_CR21","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.chembiol.2009.07.007","volume":"16","author":"S Kamisuki","year":"2009","unstructured":"Kamisuki, S. et al. A small molecule that blocks fat synthesis by inhibiting the activation of SREBP. Chem. Biol. 16, 882\u2013892 (2009).","journal-title":"Chem. Biol."},{"key":"3762_CR22","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1194\/jlr.M069583","volume":"57","author":"W Shao","year":"2016","unstructured":"Shao, W., Machamer, C. E. & Espenshade, P. J. Fatostatin blocks ER exit of SCAP but inhibits cell growth in a SCAP-independent manner. J. Lipid Res. 57, 1564\u20131573 (2016).","journal-title":"J. Lipid Res."},{"key":"3762_CR23","first-page":"1919","volume":"39","author":"S Gao","year":"2018","unstructured":"Gao, S. et al. Fatostatin suppresses growth and enhances apoptosis by blocking SREBP-regulated metabolic pathways in endometrial carcinoma. Oncol. Rep. 39, 1919\u20131929 (2018).","journal-title":"Oncol. Rep."},{"key":"3762_CR24","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1158\/1535-7163.MCT-13-0797","volume":"13","author":"X Li","year":"2014","unstructured":"Li, X., Chen, Y. T., Hu, P. & Huang, W. C. Fatostatin displays high antitumor activity in prostate cancer by blocking SREBP-regulated metabolic pathways and androgen receptor signaling. Mol. Cancer Ther. 13, 855\u2013866 (2014).","journal-title":"Mol. Cancer Ther."},{"key":"3762_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-018-0076-0","volume":"7","author":"V Brovkovych","year":"2018","unstructured":"Brovkovych, V. et al. Fatostatin induces pro- and anti-apoptotic lipid accumulation in breast cancer. Oncogenesis 7, 66 (2018).","journal-title":"Oncogenesis"},{"key":"3762_CR26","doi-asserted-by":"publisher","first-page":"4561","DOI":"10.1210\/jc.2018-01227","volume":"103","author":"VA Flores","year":"2018","unstructured":"Flores, V. A., Vanhie, A., Dang, T. & Taylor, H. S. Progesterone receptor status predicts response to progestin therapy in endometriosis. J. Clin. Endocrinol. Metab. 103, 4561\u20134568 (2018).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3762_CR27","doi-asserted-by":"publisher","first-page":"e12514","DOI":"10.1111\/cpr.12514","volume":"52","author":"C Zhou","year":"2019","unstructured":"Zhou, C. et al. Resveratrol enhances the chemotherapeutic response and reverses the stemness induced by gemcitabine in pancreatic cancer cells via targeting SREBP1. Cell Prolif. 52, e12514 (2019).","journal-title":"Cell Prolif."},{"key":"3762_CR28","doi-asserted-by":"publisher","first-page":"10089","DOI":"10.1096\/fj.201802619RR","volume":"33","author":"G Liu","year":"2019","unstructured":"Liu, G. et al. Sorafenib kills liver cancer cells by disrupting SCD1-mediated synthesis of monounsaturated fatty acids via the ATP-AMPK-mTOR-SREBP1 signaling pathway. FASEB J. 33, 10089\u201310103 (2019).","journal-title":"FASEB J."},{"key":"3762_CR29","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41588-017-0027-2","volume":"50","author":"M Chen","year":"2018","unstructured":"Chen, M. et al. An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer. Nat. Genet. 50, 206\u2013218 (2018).","journal-title":"Nat. Genet."},{"key":"3762_CR30","doi-asserted-by":"publisher","first-page":"495","DOI":"10.3389\/fncel.2018.00495","volume":"12","author":"Z Liu","year":"2018","unstructured":"Liu, Z. et al. Fractalkine\/CX3CR1 contributes to endometriosis-induced neuropathic pain and mechanical hypersensitivity in rats. Front. Cell Neurosci. 12, 495 (2018).","journal-title":"Front. Cell Neurosci."},{"key":"3762_CR31","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s00404-018-4893-3","volume":"298","author":"Y Wang","year":"2018","unstructured":"Wang, Y. et al. Roles of SIRT1\/FoxO1\/SREBP-1 in the development of progestin resistance in endometrial cancer. Arch. Gynecol. Obstet. 298, 961\u2013969 (2018).","journal-title":"Arch. Gynecol. Obstet."},{"key":"3762_CR32","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1097\/RLU.0000000000002612","volume":"44","author":"S Yamada","year":"2019","unstructured":"Yamada, S., Tsuyoshi, H., Tsujikawa, T., Okazawa, H. & Yoshida, Y. Predictive value of 16alpha-[18F]-Fluoro-17beta-estradiol PET as a biomarker of progestin therapy resistance in patients with atypical endometrial hyperplasia and low-grade endometrial cancer. Clin. Nucl. Med. 44, 574\u2013575 (2019).","journal-title":"Clin. Nucl. Med."},{"key":"3762_CR33","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/cgt.2015.52","volume":"22","author":"W Xu","year":"2015","unstructured":"Xu, W. et al. Upregulation of mitogen-inducible gene 6 triggers antitumor effect and attenuates progesterone resistance in endometrial carcinoma cells. Cancer Gene Ther. 22, 536\u2013541 (2015).","journal-title":"Cancer Gene Ther."},{"key":"3762_CR34","doi-asserted-by":"publisher","first-page":"28042","DOI":"10.18632\/oncotarget.15886","volume":"8","author":"Z Zhuo","year":"2017","unstructured":"Zhuo, Z. & Yu, H. miR-205 inhibits cell growth by targeting AKT-mTOR signaling in progesterone-resistant endometrial cancer Ishikawa cells. Oncotarget 8, 28042\u201328051 (2017).","journal-title":"Oncotarget"},{"key":"3762_CR35","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/0304-3835(92)90180-4","volume":"62","author":"PG Satyaswaroop","year":"1992","unstructured":"Satyaswaroop, P. G., Clarke, C. L., Zaino, R. J. & Mortel, R. Apparent resistance in human endometrial carcinoma during combination treatment with tamoxifen and progestin may result from desensitization following downregulation of tumor progesterone receptor. Cancer Lett. 62, 107\u2013114 (1992).","journal-title":"Cancer Lett."},{"key":"3762_CR36","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/0090-8258(88)90270-3","volume":"31","author":"JT Chambers","year":"1988","unstructured":"Chambers, J. T. et al. Estrogen and progestin receptor levels as prognosticators for survival in endometrial cancer. Gynecol. Oncol. 31, 65\u201381 (1988).","journal-title":"Gynecol. Oncol."},{"key":"3762_CR37","doi-asserted-by":"publisher","first-page":"4133","DOI":"10.1007\/s13277-015-3047-5","volume":"36","author":"Y Sun","year":"2015","unstructured":"Sun, Y. et al. SREBP1 regulates tumorigenesis and prognosis of pancreatic cancer through targeting lipid metabolism. Tumour Biol. 36, 4133\u20134141 (2015).","journal-title":"Tumour Biol."},{"key":"3762_CR38","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.3892\/or.2014.3521","volume":"32","author":"L Lin","year":"2014","unstructured":"Lin, L. et al. SIRT1 promotes endometrial tumor growth by targeting SREBP1 and lipogenesis. Oncol. Rep. 32, 2831\u20132835 (2014).","journal-title":"Oncol. Rep."},{"key":"3762_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09676-y","volume":"10","author":"Y Perone","year":"2019","unstructured":"Perone, Y. et al. SREBP1 drives Keratin-80-dependent cytoskeletal changes and invasive behavior in endocrine-resistant ERalpha breast cancer. Nat. Commun. 10, 2115 (2019).","journal-title":"Nat. Commun."},{"key":"3762_CR40","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/S0090-8258(02)00008-2","volume":"88","author":"S Wang","year":"2003","unstructured":"Wang, S. et al. Mechanisms involved in the evolution of progestin resistance in human endometrial hyperplasia\u2013precursor of endometrial cancer. Gynecol. Oncol. 88, 108\u2013117 (2003).","journal-title":"Gynecol. Oncol."},{"key":"3762_CR41","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1007\/s10147-019-01404-2","volume":"24","author":"Y Wang","year":"2019","unstructured":"Wang, Y. et al. Prolonged conservative treatment in patients with recurrent endometrial cancer after primary fertility-sparing therapy: 15-year experience. Int. J. Clin. Oncol. 24, 712\u2013720 (2019).","journal-title":"Int. J. Clin. Oncol."},{"key":"3762_CR42","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/modpathol.2009.25","volume":"22","author":"X Chen","year":"2009","unstructured":"Chen, X. et al. Aberrant survivin expression in endometrial hyperplasia: another mechanism of progestin resistance. Mod. Pathol. 22, 699\u2013708 (2009).","journal-title":"Mod. Pathol."}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-03762-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-03762-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-03762-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T09:10:27Z","timestamp":1669972227000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-03762-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,26]]},"references-count":42,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["3762"],"URL":"https:\/\/doi.org\/10.1038\/s41419-021-03762-0","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,26]]},"assertion":[{"value":"30 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All animal work procedures were approved by the Ethics Committee of the Shandong University Qilu Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}],"article-number":"544"}}